Rapacuronium
 |
This article relies largely or entirely upon a single source. Please help improve this article by introducing citations to additional sources. Discussion about the problems with the sole source used may be found on the talk page. (November 2007) |
 |
|
|---|---|
| Systematic (IUPAC) name | |
| (2β,3α,5α,16β,17β)-3-(acetyloxy)-16-(1-allylpiperidinium-1-yl)-2-piperidin-1-yl-17-(propionyloxy)androstane bromide | |
| Clinical data | |
| Pregnancy cat. | C(US) |
| Legal status | Withdrawn (U.S) |
| Routes | Intravenous |
| Pharmacokinetic data | |
| Bioavailability | Not applicable |
| Protein binding | Variable |
| Metabolism | Hydrolyzed to active metabolites CYP system not involved |
| Half-life | 141 minutes (mean) |
| Excretion | Renal and fecal |
| Identifiers | |
| CAS number | 156137-99-4 |
| ATC code | None |
| PubChem | CID 5311398 |
| DrugBank | DB04834 |
| ChemSpider | 4470889  |
| ChEMBL | CHEMBL1201352  |
| Synonyms | [(2S, 3S, 5S, 8R, 9S, 10S, 13S, 14S, 16S, 17S)-3-acetyloxy-10,13-dimethyl-2-(1-piperidyl)-16-(1-prop-2-enyl-3,4,5,6-tetrahydro-2H-pyridin-1-yl)-2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ,11 ,12 ,14, 15, 16, 17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoate |
| Chemical data | |
| Formula | C37H61N2O4+ |
| Mol. mass | 597.891 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
Rapacuronium (Raplon) is a rapidly acting, non-depolarizing neuromuscular blocker formerly used in modern anaesthesia, to aid and enable endotracheal intubation, which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes in intensive care. As a non-depolarizing agent it did not cause initial stimulation of muscles before weakening them.
Due to risk of fatal bronchospasm it was withdrawn from the United States market by Organon on March 27, 2001.[1]
[edit] References
- ^ Shapse, Deborah (March 27, 2001). Voluntary Market WithdrawalPDF (10.8 KiB). Organon International. Retrieved on 2007-04-02.
|
